|
|
 |
|
Viewing report
|
|
|
|
China’s Attraction and Strategies to Work with It: Analysis of Best Strategies for Western Pharmaceutical and Biotech Companies to Partner with Chinese Pharmaceutical Companies
JZMed Inc., July 2008, Pages: 162
Despite the fact that China has become attractive to the Western pharmaceutical and biotechnology companies because of its sizeable yet still rising pharmaceutical market and abundant yet still low-cost manpower resources, it is still challenging to many Western pharma/biotech companies as for how to timely grab the opportunities presented by this market and how to effectively utilize the resources currently available in that country.
On the other hand, since things are changing rapidly in China at present time, including its pharmaceutical market and the cost of its abundant manpower resources, Western pharma/biotech companies would have found themselves in the end that they have missed what is available presently in China if they decided to wait until all issues they are concerned with are completely cleared out before starting thinking of entering the Chinese market. In fact, it is all related to what strategies the Western companies should take when facing such challenges. There are, in fact, many proven ways, both practical and effective, for these companies to adopt to enter the Chinese market.
This report is thus designed and prepared to help these companies identify the best strategies suitable for them to pursue the China opportunity.
Main features of the report:
- The report is written by industry experts who knows both the Western pharmaceutical/biotech industry and the Chinese pharmaceutical industry, and is based on a long time study of the Chinese pharmaceutical industry.
- The report includes rich, first-hand information about the Chinese pharmaceutical market, Chinese pharmaceutical industry as well as the Chinese culture in particular their business philosophy and behaviors in business conduct.
- The report also first time released a complete and comprehensive package of strategies suitable to any size of Western pharma/biotech companies to pursue their China opportunity. It analyzed in depth both the advantages and disadvantages of each of these strategies, and provides the useful strategies of how to overcome challenges when entering the Chinese market.
- More importantly, the report illustrated these strategies with case studies of abundant real examples.
- In addition, the report includes detailed information of 48 best Chinese companies in the areas of traditional pharmaceutical, biotechnology, contract pharmaceutical research, and contract pharmaceutical manufacturing, including their capabilities in R&D and/or manufacturing.
- The report also describes in detail the activities of 66 Western companies currently pursuing opportunities in China. These companies include major pharma/biopharma companies, small-sized biotech companies, multinational CROs, generic drug makers, as well as venture capital investors.
Following questions answered by the report:
- What does China possess? How could this country be an alternative place of resources to the Western pharma and biotech companies?
- What do the readily available resources in China mean to the Western companies?
- Why is China as an emerging pharmaceutical market important to the Western companies? How will this market possibly develop in near future?
- What can Chinese pharmaceutical companies do to help Western companies?
- Who can go to China and what strategies should they employ?
- What are the best strategies to tap the resources readily available in China?
- What are the secrets of Chinese culture in business conduct? How to effectively deal with them?
- How to effectively collaborate with a Chinese company and establish a good relationship with them?
Methodologies the report employed:
- The report first conducted a complete and thorough analysis about all challenges the Western pharmaceutical and biotech companies presently experience and the actions they are taking trying to exit quickly from the current downturn situation. It then analyzed the advantages and disadvantages of these actions. Based on the analysis, the report then pointed out what are urgently needed for these pharma/biotech companies not only to make a quick turnaround but also to be prospective in their long term development.
- The report then analyzed what China, based on its rising pharmaceutical market and readily available abundant manpower resources in its pharmaceutical industry, could offer to help the Western companies overcome the difficulties, including all possible options the Western companies can take.
- Based on the analysis of what are urgently needed and what are readily available on both sides, the report then conducted a matching process. Based on the results discovered in the matching process, it identified the best strategies for the Western companies to tap the available resources in China.
- The report further analyzed and identified all possible challenges the Western companies may face when entering the Chinese market with the emphasis on the cultural difference in Chinese business conduct. It then made suggestions to all Western companies, both large and startup, of the best strategies to circumvent the hurdles in order to effectively work with China, both people and companies in that country.
Who should buy the report:
- The report is a valuable guide and a must-read book to executives of the pharmaceutical and biotechnology companies, both large and startup, who would like to incorporate the best strategies into their corporate development plans in order to effectively tap the readily available resources in China.
- The report is also a useful reference book to those executives in the financial investment industry and even government agencies who wish to have a better understanding about China and the Chinese culture as well.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Guide to Pharmaceutical Outsourcing in China: A Handbook for Pharmaceutical and Biotechnology Companies Planning to Outsource to China
China Pharma Outsourcing Market By 2015
Comparison of Pharma Outsourcing between China and India
China Pharma Outsourcing Annual Review 2009
Advantages and Disadvantages of Increasing Pharmaceutical R&D Outsourcing to India and China
China Biotech 2008
200 China-based Best CROs and CMOs
Top 100 Best Pharma Outsourcing Service Providers in China and India
The Pharmaceutical Industry 2008: Current and Future Trends and Strategic Issues Shaping Pharma
Intellectual Property and Outsourcing in China: Minimizing Risk whilst Maximizing Return on Investment
Biomarkers and Tests for Pharma/ Biotech R&D – Companies Products and WW Market, 2006-2011
Contract Research Organization Market- What Pharmaceutical and Biotechnology Companies Want
|
|
|
|
